Luvixasertib

Overview

CFI-402257 is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC 50 of 1.7 nM for TTK in vitro. CFI-402257 has anti-cancer activity.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > Mps1

Product Information

• Catalog No.: HY-101340
• CAS No.: 1610759-22-2
• Molecular Formula: C28H30N6O3
• Molecular Weight: 498.58
• Purity: 99.9600%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source